- Home
- HTGC vs RYTM Comparison
HTGC vs RYTM Comparison
Compare HTGC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTGC
- RYTM
- Stock Information
- Founded
- HTGC 2003
- RYTM 2008
- Country
- HTGC United States
- RYTM United States
- Employees
- HTGC N/A
- RYTM N/A
- Industry
- HTGC Investment Managers
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- HTGC Finance
- RYTM Health Care
- Exchange
- HTGC Nasdaq
- RYTM Nasdaq
- Market Cap
- HTGC 3.2B
- RYTM 3.8B
- IPO Year
- HTGC 2005
- RYTM 2017
- Fundamental
- Price
- HTGC $17.48
- RYTM $57.38
- Analyst Decision
- HTGC Buy
- RYTM Strong Buy
- Analyst Count
- HTGC 8
- RYTM 12
- Target Price
- HTGC $20.81
- RYTM $75.42
- AVG Volume (30 Days)
- HTGC 1.1M
- RYTM 691.8K
- Earning Date
- HTGC 05-01-2025
- RYTM 05-07-2025
- Dividend Yield
- HTGC 10.76%
- RYTM N/A
- EPS Growth
- HTGC N/A
- RYTM N/A
- EPS
- HTGC 1.33
- RYTM N/A
- Revenue
- HTGC $491,549,000.00
- RYTM $136,863,000.00
- Revenue This Year
- HTGC $7.95
- RYTM $43.84
- Revenue Next Year
- HTGC $8.96
- RYTM $65.62
- P/E Ratio
- HTGC $13.13
- RYTM N/A
- Revenue Growth
- HTGC 3.02
- RYTM 48.88
- 52 Week Low
- HTGC $15.65
- RYTM $35.17
- 52 Week High
- HTGC $22.04
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- HTGC 44.53
- RYTM 43.00
- Support Level
- HTGC $17.27
- RYTM $62.69
- Resistance Level
- HTGC $18.13
- RYTM $65.53
- Average True Range (ATR)
- HTGC 0.31
- RYTM 3.04
- MACD
- HTGC 0.04
- RYTM -0.73
- Stochastic Oscillator
- HTGC 25.00
- RYTM 1.14
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.